What drove the sales growth in the third quarter?

Sales growth was driven by strong performance across all segments, particularly Pharmaceuticals and Medical Devices & Diagnostics. International sales showed robust growth, supported by favorable currency exchange rates. Key product performances in RISPERDAL, REMICADE, DURAGESIC, and TOPAMAX contributed significantly to the Pharmaceutical segment's revenue.

Are there any notable challenges or declines in specific product lines?

Yes, the PROCRIT/EPREX product line experienced a sales decline of 11.7% in the third quarter due to increased competition. Additionally, Cordis's U.S. sales of the CYPHER stent decreased by 37% in the third quarter due to competitive pressures, although international sales for Cordis showed strong growth.

What is the company's outlook regarding legal proceedings?

Johnson & Johnson is involved in numerous legal proceedings, including product liability cases and patent litigations. While the company is vigorously defending itself, it acknowledges that the ultimate outcome of these matters cannot be estimated with certainty. However, management believes that any potential liabilities, net of amounts accrued, are not expected to have a material adverse effect on the consolidated financial position, though resolution could impact results of operations and cash flows in a specific period.

How is the company managing its research and development investments?

Research and development expenditures remain a significant focus. For the first nine months of 2004, R&D costs were $3.5 billion, an increase of 8.8% over the prior year. This investment supports new product development, product improvements, and regulatory compliance across all business segments.

JNJ 10-Q Quarterly Report Q3 FY2004 — Revenue, Net Income, EPS

Summary

Johnson & Johnson reported a strong third quarter and nine-month performance for the period ending September 26, 2004. Worldwide sales increased by 10.5% to $11.6 billion for the quarter and by 13.0% to $34.6 billion for the nine months, with a significant portion of growth driven by favorable currency exchange rates and strong international performance. Net earnings for the quarter rose to $2.34 billion ($0.78 per diluted share), up from $2.07 billion ($0.69 per diluted share) in the prior year. The Pharmaceutical segment demonstrated robust growth, with notable increases in sales for RISPERDAL, REMICADE, DURAGESIC, and TOPAMAX, though PROCRIT sales experienced a decline due to increased competition. The Medical Devices and Diagnostics segment also showed solid growth, particularly internationally, driven by DePuy's orthopaedic products and Vision Care. The Consumer segment experienced steady growth, bolstered by acquisitions and strong brand performance in skincare and OTC products. The company's financial position remains solid, with substantial cash generated from operations and ongoing dividend payments to shareholders, underscoring its commitment to returning value to investors.

Key Highlights

1Worldwide sales increased by 10.5% to $11.6 billion for the third quarter and by 13.0% to $34.6 billion for the first nine months of 2004.
2Net earnings for the third quarter were $2.34 billion, or $0.78 per diluted share, compared to $2.07 billion, or $0.69 per diluted share, in the prior year.
3The Pharmaceutical segment showed strong growth, with notable sales increases in RISPERDAL, REMICADE, DURAGESIC, and TOPAMAX, despite a decline in PROCRIT sales.
4The Medical Devices and Diagnostics segment reported a 7.0% increase in third-quarter sales, with strong international performance and a significant boost from Cordis's international sales following the launch of CYPHER in Japan.
5The Consumer segment achieved a 9.9% increase in third-quarter sales, driven by acquisitions and continued strength in key brands like NEUTROGENA and JOHNSON'S Baby products.
6Operating cash flow for the first nine months of 2004 was $8.7 billion, an increase of $1.6 billion over the prior year.
7The company continues to return value to shareholders through regular cash dividends, with a dividend of $0.285 per share declared for the fourth quarter of 2004.

JOHNSON & JOHNSON Quarterly Report for Q3 Ended Sep 26, 2004

Summary

Key Highlights

Frequently Asked Questions